BIO-TECHNE CORP shareholders Q2 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
NEW YORK LIFE INVESTMENT MANAGEMENT LLC 5,671$1,966,0000.02%
COMERICA BANK 7,849$2,749,0000.02%
CREDIT SUISSE AG/ 60,220$20,874,0000.02%
TWO SIGMA ADVISERS, LP 22,192$7,693,0000.02%
TOKIO MARINE ASSET MANAGEMENT CO LTD 708$245,0000.02%
COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS 5,712$1,980,0000.02%
BRYN MAWR TRUST Co 1,295$449,0000.02%
PRUDENTIAL FINANCIAL INC 37,149$12,923,0000.02%
Foundry Partners, LLC 1,027$356,0000.02%
PRINCIPAL FINANCIAL GROUP INC 83,426$28,919,0000.02%
JANICZEK WEALTH MANAGEMENT, LLC 179$69,0000.02%
Cresset Asset Management, LLC 4,915$1,698,0000.02%
ROYAL LONDON ASSET MANAGEMENT LTD 12,493$4,333,0000.02%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 32,399$11,231,0000.02%
ADVISOR PARTNERS LLC 830$288,0000.02%
LOS ANGELES CAPITAL MANAGEMENT LLC 11,831$4,101,0000.02%
Skandinaviska Enskilda Banken AB (publ) 7,856$2,723,0000.02%
PARK AVENUE SECURITIES LLC 2,971$1,030,0000.02%
Retirement Systems of Alabama 13,006$4,508,0000.02%
Crossmark Global Holdings, Inc. 2,058$714,0000.02%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.